Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04113343 · ClinicalTrials.gov registry record · Phase 1
Oral Remimazolam With and Without Alcohol in Healthy Female Subjects
A Phase 1 study of Safety Issues, sponsored by Paion UK.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT04113343: Completed Phase 1 study of Safety Issues, sponsored by Paion UK.
NCT04113343 is a Phase 1 study of Safety Issues that has completed, run by Paion UK. The registered enrollment target is 21 participants, below the 118-participant average among 13 other Safety Issues trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04113343, a Phase 1 study of Safety Issues, has completed, sponsored by Paion UK.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 1 Study to Determine the Single-dose Pharmacodynamics, Pharmacokinetics, and Safety and Tolerability of Remimazolam Following Oral Administration With and Without Alcohol in Healthy Female Subjects
Primary Outcome
PAL Test was conducted using the software CANTAB (Cambridge Cognition)
Conditions Studied
Interventions
- DRUG Remimazolam
- OTHER Alcohol
Study Locations (1)
Utah
- PRA Health Sciences (PRA) - Early Development Services - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-05-30 |
| Est. Completion | 2017-08-09 |
| Phase | Phase 1 |
What the finished NCT04113343 record still lists
NCT04113343 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 118-participant average among 13 other Safety Issues trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Safety Issues appearing as the primary indexed condition, and to 2 interventions - of which Remimazolam is the first listed.
NCT04113343 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT04113343 about?
NCT04113343 is a clinical study titled "Oral Remimazolam With and Without Alcohol in Healthy Female Subjects". A Phase 1 Study to Determine the Single-dose Pharmacodynamics, Pharmacokinetics, and Safety and Tolerability of Remimazolam Following Oral Administration With and Without Alcohol in Healthy Female Subjects
What is the current status of trial NCT04113343?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2017-05-30. Estimated completion is 2017-08-09.
What conditions does trial NCT04113343 study?
This clinical trial studies the following conditions: Safety Issues.
What interventions are being tested in trial NCT04113343?
The interventions under investigation include: Remimazolam (DRUG), Alcohol (OTHER).
Who is sponsoring clinical trial NCT04113343?
This trial is sponsored by Paion UK, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04113343 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Safety Issues
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04113343's enrollment target sits among peer trials
21 10th of 13 higher than 3 of 13 other Safety Issues trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Safety Issues trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1 Study of the Safety and Tolerability of ICM20 in Adults
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1 Study of EXT608 in Healthy Adults
COMPLETED · Phase 1
-
Rectal Insert TAF/EVG Pre-Exposure Prophylaxis (RITE PrEP) Study
COMPLETED · Phase 1
-
Pupillary Unrest in Ambient Light, and Relationship to Opioid-Induced Respiratory Depression
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI